TGFB1 and neoplasm: A recent preclinical study has shown that the lack of response to Atezolizumab therapy was associated with TGFβ signature in fibroblasts and exclusion of CD8+ T-effector cells from tumor parenchyma in metastatic urothelial tumors (Mariathasan et al., 2018).